-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
-
A randomized controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
-
In This Issue: Guidelines for prediabetes from The American College of Endocrinology; statins for the prevention of dementia? Possible help for women suffering from sexual side effects while on antidepressants; government incentives for electronic prescribing; FDA Actions.
-
A large body of literature has developed over the last decade consistently showing improved outcomes with increased use of critical care physicians in the management of patients in the ICU.
-
Delayed ischemic insults are a major cause of morbidity and mortality in spontaneous subarachnoid hemorrhage (SAH).
-
This prospective cohort study was carried out in a 30-bed medical-surgical ICU in London to determine whether culturing throat and rectal swabs would identify more cases of methicillin-resistant Staphylococcus aureus (MRSA) colonization than just swabbing at keratinized skin carriage sites such as the anterior nares, perineum, and axillae.